Repligen Co. (NASDAQ:RGEN) Shares Sold by Greenleaf Trust

Greenleaf Trust lowered its position in Repligen Co. (NASDAQ:RGEN) by 30.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,316 shares of the biotechnology company’s stock after selling 567 shares during the quarter. Greenleaf Trust’s holdings in Repligen were worth $237,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in RGEN. Parnassus Investments LLC acquired a new position in Repligen in the 3rd quarter worth $87,475,000. Allspring Global Investments Holdings LLC acquired a new position in Repligen in the 3rd quarter worth $41,540,000. Artisan Partners Limited Partnership lifted its holdings in Repligen by 11.3% in the 3rd quarter. Artisan Partners Limited Partnership now owns 1,556,873 shares of the biotechnology company’s stock worth $247,558,000 after buying an additional 157,807 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Repligen by 13.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,195,629 shares of the biotechnology company’s stock worth $190,117,000 after purchasing an additional 137,220 shares during the last quarter. Finally, Artemis Investment Management LLP bought a new stake in shares of Repligen in the 4th quarter worth about $22,552,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Transactions at Repligen

In other news, CEO Anthony Hunt sold 16,707 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $197.44, for a total value of $3,298,630.08. Following the completion of the sale, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at approximately $36,575,562.56. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, COO James Bylund sold 4,373 shares of the stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total transaction of $866,203.84. Following the completion of the sale, the chief operating officer now directly owns 14,135 shares of the company’s stock, valued at $2,799,860.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Anthony Hunt sold 16,707 shares of the stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the sale, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at $36,575,562.56. The disclosure for this sale can be found here. In the last three months, insiders sold 25,597 shares of company stock valued at $5,039,532. Company insiders own 1.20% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on RGEN shares. Stifel Nicolaus boosted their target price on shares of Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. KeyCorp boosted their target price on shares of Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Repligen presently has an average rating of “Moderate Buy” and a consensus price target of $196.70.

Repligen Trading Down 2.0 %

Shares of NASDAQ:RGEN opened at $167.86 on Thursday. The company has a 50 day moving average of $185.86 and a 200-day moving average of $173.52. The firm has a market cap of $9.37 billion, a P/E ratio of 233.14, a P/E/G ratio of 5.61 and a beta of 1.02. Repligen Co. has a twelve month low of $110.45 and a twelve month high of $211.13. The company has a current ratio of 7.02, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.33. The company had revenue of $155.74 million during the quarter, compared to analyst estimates of $155.38 million. Repligen had a net margin of 6.51% and a return on equity of 5.00%. The business’s revenue for the quarter was down 16.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.68 EPS. As a group, analysts anticipate that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.